SMNR

Semnur Pharmaceuticals, Inc.

Price Chart

Latest Quote

$0.36

+0.04 (+11.89%)

Current Price

Previous Close	$0.32
Open	$0.30
Day High	$0.50
Day Low	$0.30
Volume	486

Fetched: 2026-10-31T16:01:02

Stock Information

Shares Outstanding	230.21M
Total Debt	$23.05M
Cash Equivalents	$39K
Net Income	$-167.68M
Sector	Healthcare
Industry	Biotechnology
Market Cap	$82.43M
EPS (TTM)	$-0.81
Exchange	PNK

🌐 Visit Website

📊 Comprehensive Analysis

Company Data

Enterprise Value	$105.44M
Income	$-167.68M
Book/sh	$-0.13
Cash/sh	$0.00
Employees	5

Financial Ratios

Quick Ratio	0.00
Current Ratio	0.11

Returns & Margins

ROA

-1900.20%

Ownership

Insider Ownership	84.28%
Institutional Ownership	0.00%
Insider & Institutional transactions data not available

Valuation Ratios

P/B

-2.78

Analyst Data

Recommendation

none

Technical Indicators

SMA20	$0.42
SMA50	$0.49
SMA200	$3.96
RSI	45.61
ATR	0.1308

Shares Float	36.19M
Volatility	-0.03
Rel Volume	0.54

Performance History

Week	-28.39%
Month	-37.18%
Quarter	-59.86%
6 Months	-95.52%
YTD	-98.44%
Year	-96.02%
10 Years	-98.21%

Stock Score: ⭐ Premium

Based on debt, profitability, growth, and cash flow metrics

⭐ Premium Feature

Recent Price History

Date	Close	Volume
2026-10-30	$0.36	2,079
2026-10-29	$0.32	5,588
2026-10-28	$0.30	1,193
2026-10-27	$0.50	10,500
2026-10-26	$0.51	872
2026-10-23	$0.50	3,588
2026-10-22	$0.38	372
2026-10-21	$0.38	1,469
2026-10-20	$0.40	10,327
2026-10-19	$0.43	1,016
2026-10-16	$0.40	772
2026-10-15	$0.51	1,245
2026-10-14	$0.38	2,590
2026-10-13	$0.38	5,147
2026-10-12	$0.43	1,899
2026-10-09	$0.54	13,189
2026-10-08	$0.42	4,496
2026-10-07	$0.42	4,158
2026-10-06	$0.42	1,046
2026-10-05	$0.45	6,104
2026-10-02	$0.45	3,552
2026-10-01	$0.57	3,678
2026-09-30	$0.56	14,901

About Semnur Pharmaceuticals, Inc.

Semnur Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its lead product candidate is SP-102, a novel viscous gel formulation of corticosteroid to treat lumbosacral radicular pain, or sciatica, which is in the second Phase 3 study. The company was founded in 2013 and is headquartered in Palo Alto, California. Semnur Pharmaceuticals, Inc. operates as a subsidiary of Scilex Holding Company.

📰 Latest News

No news articles available at the moment. Check back later for updates on SMNR.

Period:

Income Statement (Annual)

Metric	2024-12-31	2023-12-31	2022-12-31
Revenue
Total Revenue	$0	$0	$0
Operating Revenue	$0	$0	$0
Expenses
Total Expenses	$4,690,000	$3,261,000	$3,765,000
Operating Expense	$4,690,000	$3,261,000	$3,765,000
General And Administrative Expense	$2,981,000	$1,640,000	$1,647,000
Income & Earnings
Net Income From Continuing Operation Net Minority Interest	$-4,690,000	$-3,261,000	$-3,765,000
Normalized Income	$-4,690,000	$-3,261,000	$-3,765,000
Net Income From Continuing And Discontinued Operation	$-4,690,000	$-3,261,000	$-3,765,000
Total Operating Income As Reported	$-4,690,000	$-3,261,000	$-3,765,000
Net Income Common Stockholders	$-4,690,000	$-3,261,000	$-3,765,000
Net Income	$-4,690,000	$-3,261,000	$-3,765,000
Net Income Including Noncontrolling Interests	$-4,690,000	$-3,261,000	$-3,765,000
Net Income Continuous Operations	$-4,690,000	$-3,261,000	$-3,765,000
Pretax Income	$-4,690,000	$-3,261,000	$-3,765,000
Operating Income	$-4,690,000	$-3,261,000	$-3,765,000
Per Share
Diluted EPS	$-0.02	$-0.01	$-0.02
Basic EPS	$-0.02	$-0.01	$-0.02
Other
Tax Effect Of Unusual Items	$0	$0	$0
Tax Rate For Calcs	$0	$0	$0
Normalized EBITDA (Bullshit earnings)	$-4,690,000	$-3,261,000	$-3,765,000
EBITDA (Bullshit earnings)	$-4,690,000	$-3,261,000	$-3,765,000
EBIT	$-4,690,000	$-3,261,000	$-3,765,000
Diluted Average Shares	$240,082,286	$240,082,286	$240,082,286
Basic Average Shares	$240,082,286	$240,082,286	$240,082,286
Diluted NI Availto Com Stockholders	$-4,690,000	$-3,261,000	$-3,765,000
Research And Development	$1,709,000	$1,621,000	$2,118,000
Selling General And Administration	$2,981,000	$1,640,000	$1,647,000
Other Gand A	$2,981,000	$1,640,000	$1,647,000

Fetched: 2026-02-02

Balance Sheet (Annual)

Metric	2024-12-31	2023-12-31	2022-12-31
Assets
Net Tangible Assets	$-42,784,000	$-38,094,000	$-34,833,000
Total Assets	$6,684,000	$703,000	$762,000
Total Non Current Assets	$689,000	$689,000	$689,000
Current Assets	$5,995,000	$14,000	$73,000
Other Current Assets	$5,981,000	-	-
Prepaid Assets	$2,000	$2,000	$45,000
Cash Cash Equivalents And Short Term Investments	$12,000	$12,000	$28,000
Cash And Cash Equivalents	$12,000	$12,000	$28,000
Debt
Net Debt	$49,421,000	$37,889,000	$35,372,000
Total Debt	$49,433,000	$37,901,000	$35,400,000
Long Term Debt And Capital Lease Obligation	$49,433,000	$37,901,000	$35,400,000
Long Term Debt	$49,433,000	$37,901,000	$35,400,000
Liabilities
Total Liabilities Net Minority Interest	$49,468,000	$38,797,000	$35,595,000
Total Non Current Liabilities Net Minority Interest	$49,433,000	$37,901,000	$35,400,000
Current Liabilities	$35,000	$896,000	$195,000
Payables And Accrued Expenses	$35,000	$896,000	$195,000
Equity
Common Stock Equity	$-42,784,000	$-38,094,000	$-34,833,000
Total Equity Gross Minority Interest	$-42,784,000	$-38,094,000	$-34,833,000
Stockholders Equity	$-42,784,000	$-38,094,000	$-34,833,000
Retained Earnings	$-115,384,000	$-110,694,000	$-107,433,000
Other
Ordinary Shares Number	$240,082,286	$240,082,286	$240,082,286
Share Issued	$240,082,286	$240,082,286	$240,082,286
Tangible Book Value	$-42,784,000	$-38,094,000	$-34,833,000
Invested Capital	$6,649,000	$-193,000	$567,000
Working Capital	$5,960,000	$-882,000	$-122,000
Total Capitalization	$6,649,000	$-193,000	$567,000
Additional Paid In Capital	$72,598,000	$72,598,000	$72,598,000
Capital Stock	$2,000	$2,000	$2,000
Common Stock	$2,000	$2,000	$2,000
Preferred Stock	$0	$0	-
Current Accrued Expenses	$35,000	$896,000	$195,000
Net PPE	$689,000	$689,000	$689,000
Accumulated Depreciation	$-25,000	$-25,000	$-25,000
Gross PPE	$714,000	$714,000	$714,000
Construction In Progress	$689,000	$689,000	$689,000
Machinery Furniture Equipment	$25,000	$25,000	$25,000

Fetched: 2026-02-02

Cash Flow Statement (Annual)

Metric	2024-12-31	2023-12-31	2022-12-31
Free Cash Flow
Free Cash Flow	$-4,891,000	$-1,677,000	$-4,043,000
Operating Activities
Operating Cash Flow	$-4,891,000	$-1,677,000	$-4,043,000
Cash Flow From Continuing Operating Activities	$-4,891,000	$-1,677,000	$-4,043,000
Financing Activities
Financing Cash Flow	$4,891,000	$1,661,000	$3,974,000
Cash Flow From Continuing Financing Activities	$4,891,000	$1,661,000	$3,974,000
Net Other Financing Charges	$-5,981,000	-	-
Other
Issuance Of Debt	$10,872,000	$1,661,000	$3,974,000
End Cash Position	$12,000	$12,000	$28,000
Beginning Cash Position	$12,000	$28,000	$97,000
Net Issuance Payments Of Debt	$10,872,000	$1,661,000	$3,974,000
Net Long Term Debt Issuance	$10,872,000	$1,661,000	$3,974,000
Long Term Debt Issuance	$10,872,000	$1,661,000	$3,974,000
Change In Working Capital	$-861,000	$744,000	$-1,150,000
Change In Payables And Accrued Expense	$-861,000	$701,000	$-1,340,000
Change In Accrued Expense	$-861,000	$701,000	$-563,000
Change In Prepaid Assets	$0	$43,000	$190,000
Stock Based Compensation	$660,000	$840,000	$872,000
Net Income From Continuing Operations	$-4,690,000	$-3,261,000	$-3,765,000
Changes In Cash	-	$-16,000	$-69,000
Change In Account Payable	-	$0	$-777,000
Change In Payable	-	-	$-777,000

Fetched: 2026-02-02